Evaluating Response to Vitamin D3 and K2 Supplementation in Healthcare Personnel
Madigan Army Medical Center · NCT07199829
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–69 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 96
- US sites recruiting
- 1
- Study start
- March 27, 2025
- Record last updated
- September 30, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The main purpose of this research study is to learn about the effects of supplemental vitamin D3 and vitamin K2 on blood levels and the gut microbial community, called the gut microbiome. There are many influences on blood levels of vitamin D and K to include your dietary intake, lifestyle behaviors (physical activity, sleep), genetic alterations in metabolism of these vitamins, and the gut microbial abundance and diversity. You will be asked to take one capsule containing vitamin D3 (125 mcg), vitamin K2 (180 mcg), a combination of vitamins D3 and K2 (same doses as previous), or a placebo powder for 90 days. You will also be asked to complete questionnaires, undergo body composition and blood pressure measurements, provide blood samples and a stool swab, all on 2 occasions about 3 - 4 months apart. By conducting this study, we aim to identify the frequency of common genetic alterations in vitamins D and K metabolism and establish the impact on the gut microbiome for the first time. Your participation in this study will last about 4 - 6 months and include up to 3 visits.
Being studied: Vitamin Arm 1; Vitamin Arm 2; Vitamin Arm 3; Placebo
Conditions: Hypovitaminosis D; Hypovitaminosis
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- able to read and understand English
- 25 OHD serum level equal to or less than 30 ng/mL
- willing to discontinue vitamin D3 and/or K2 supplements for 4.5 months
- military beneficiary (Active Duty, Retired, Dependent)
- remaining employed at workplace for 6 months
Exclusion Criteria
- Diagnosed medical condition that prevents nutrient absorption from food (e.g. Inflammatory Bowel Disease, Celiac Disease, post-Roux-en-Y/Gastric sleeve surgery)
- Pregnant or breastfeeding
- Current antibiotic use or within past 3 months
- Current anticoagulant use or within past 3 months
- Current weight loss or fat malabsorption medication use (e.g. Glucagon-Like Peptide 1 agonists, Orlistat)
- Allergies or sensitivities to methylcellulose, vitamin D (D3, D2), or vitamin K (K2, Menaquinone-4, Menaquinone-7)
Recruiting US locations
Madigan Army Medical Center
Tacoma, WA 98431
Site contact: Mary S McCarthy, PhD · 253-968-3695 · mary.s.mccarthy1.civ@health.mil
Study contacts (from the official record)
- Mary S McCarthy, PhD · 253-968-3695 · mary.s.mccarthy1.civ@health.mil
- Hyojin C Yi, BSN · 253-968-2898 · hyojin.c.yi.ctr@health.mil
Similar studies in Washington
All nutrition & metabolism studies in Washington →- RecruitingHealthy volunteers
Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis
ContextVision AB
- Location
- Seattle, WA
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
GlaxoSmithKline
- Location
- Seattle, WA + 46 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
GlaxoSmithKline
- Location
- Seattle, WA + 62 other US sites
- Eligibility basics
- Ages 18–75
- Recruiting
KiteLock 4% EDTA Lock Solution for the Prevention of Occlusions in Children With Intestinal Failure
SterileCare Inc.
- Location
- Seattle, WA + 6 other US sites
- Eligibility basics
- Ages 1 mo–18